PRESS RELEASE WASHINGTON, DC – The American Pharmacists Association launched its newest education training program, ADAPT, from the 2015 APhA Annual Exposition and Meeting, APhA2015. ADAPT can be a transformative, online patient treatment skills development program created for practicing pharmacists in all settings specifically. ADAPT delivers evidence-based articles from leading experts in an interactive online learning structure read . The evolving health care system and pursuit of pharmacist provider status is changing business models and growing scope of practice in pharmacies across the country. ADAPT might help turn issues into possibilities for pharmacists. ADAPT shall increase pharmacists’ confidence and help them integrate new patient care skills and systematic processes and tools into everyday practice.

ARIAD Pharmaceuticals completes rolling submission of ponatinib NDA with FDA ARIAD Pharmaceuticals, Inc. today announced it offers finished the rolling submission of the brand new Drug Program for its investigational BCR-ABL inhibitor, ponatinib, to the U.S. Food and Drug Administration . ARIAD provided the FDA with remaining chemistry, developing, and controls data. ARIAD is searching for U.S. Marketing authorization of ponatinib in patients with resistant or intolerant chronic myeloid leukemia and Philadelphia-chromosome positive severe lymphoblastic leukemia . THE BUSINESS has requested accelerated authorization and important review of the ponatinib software by the FDA.